Trial Profile
An exploratory study of sorafenib for patients listed for transplantation due to HCC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2020
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 02 Jan 2020 Status changed from recruiting to completed as per results published in the BMC Cancer.
- 24 Sep 2013 New trial record